Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
Related News
Test that finds hidden cancer to aid survival
Source: Agencies |
February 19, 2009, Thursday
|
Print Edition
Print Edition
A MORE sensitive screening test may one day help doctors determine how far colorectal cancer has spread, giving patients a better shot at survival, according to researchers in the United States.
They said a genetic test that looks for a specific cancer biomarker known as guanylyl cyclase 2 C found hidden cancer in lymph nodes that had been missed by current screening methods.
Colorectal cancer is the fourth most common cancer in men and the third in women worldwide, striking 1.2 million people each year, according to the American Cancer Society.
"One of the unmet needs of colorectal cancer is an accurate staging method to determine how far the disease has spread," said Dr Scott Waldman of Thomas Jefferson University in Philadelphia, whose study appears in the Journal of the American Medical Association.
Waldman is a scientific adviser to Targeted Diagnostics and Therapeutics Inc in Pennsylvania, which helped fund the study.
The current testing method involves looking at a small sample of tissue from lymph nodes.
In about 25 percent of patients whose lymph nodes test clean, the cancer comes back. Waldman and colleagues wanted to see if a test that looks for the protein guanylyl cyclase C, a marker in lymph nodes associated with increased risk of recurrence of colorectal cancer, might do a better job at finding these hidden cancers.
In prior studies, Waldman and others found the protein present only in the intestinal wall and in colon cancer cells. Therefore, finding it in lymph nodes would suggest that the cancer had spread.
In the latest study, the researchers evaluated 257 people with colorectal cancer whose biopsies detected no cancer in the lymph nodes closest to where their tumors had been surgically removed.
Using the genetic test, the researchers found the cancer biomarker in 87.5 percent of patients tested. Of these, 20.9 percent had their cancer come back. That compared with only 6.3 percent of those patients whose lymph nodes tested negative for the cancer biomarker.
Waldman said that the findings suggest that the more sensitive test might help spot cancers missed in biopsies, but larger studies would be needed to tell how effective the test might be.
They said a genetic test that looks for a specific cancer biomarker known as guanylyl cyclase 2 C found hidden cancer in lymph nodes that had been missed by current screening methods.
Colorectal cancer is the fourth most common cancer in men and the third in women worldwide, striking 1.2 million people each year, according to the American Cancer Society.
"One of the unmet needs of colorectal cancer is an accurate staging method to determine how far the disease has spread," said Dr Scott Waldman of Thomas Jefferson University in Philadelphia, whose study appears in the Journal of the American Medical Association.
Waldman is a scientific adviser to Targeted Diagnostics and Therapeutics Inc in Pennsylvania, which helped fund the study.
The current testing method involves looking at a small sample of tissue from lymph nodes.
In about 25 percent of patients whose lymph nodes test clean, the cancer comes back. Waldman and colleagues wanted to see if a test that looks for the protein guanylyl cyclase C, a marker in lymph nodes associated with increased risk of recurrence of colorectal cancer, might do a better job at finding these hidden cancers.
In prior studies, Waldman and others found the protein present only in the intestinal wall and in colon cancer cells. Therefore, finding it in lymph nodes would suggest that the cancer had spread.
In the latest study, the researchers evaluated 257 people with colorectal cancer whose biopsies detected no cancer in the lymph nodes closest to where their tumors had been surgically removed.
Using the genetic test, the researchers found the cancer biomarker in 87.5 percent of patients tested. Of these, 20.9 percent had their cancer come back. That compared with only 6.3 percent of those patients whose lymph nodes tested negative for the cancer biomarker.
Waldman said that the findings suggest that the more sensitive test might help spot cancers missed in biopsies, but larger studies would be needed to tell how effective the test might be.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
